within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01C_CardiacStimulantsExclCardiacGlycosides.C01CA02_Isoprenaline;

model Isoprenaline
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 6.166666666666667e-05,
    adminDuration = 600,
    adminMass = 0.02 / 1000000,
    adminCount = 1,
    Vd = 0.0035,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0031,
    k12 = 3.6666666666666666e-05,
    k21 = 3.6666666666666666e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Isoprenaline</td></tr><tr><td>ATC code:</td><td>C01CA02</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>0.02</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>3.7</td><td>L/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Isoprenaline (also known as isoproterenol) is a synthetic non-selective beta-adrenergic agonist. It was used primarily as a bronchodilator and cardiac stimulant for the treatment of bradycardia (slow heart rate), heart block, and sometimes for asthma. Its use today is limited due to the availability of more selective agents and safety considerations.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following intravenous bolus injection.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C01CA02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Isoprenaline;
